TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10471602
Drug: Inhaled olprinone
Normalized name: Olprinone
DrugBank: Olprinone (DB16847)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Inhaled olprinone
Study: 6416401
Drug: Anatomical injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anatomical injection after diagnosis by selective tissue tension technique
Study: 6416401
Drug: Tender or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tender or trigger point localisation injection
Study: 28498655
Drug: Benzimidazole DGAT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzimidazole DGAT1 inhibitor 9
Study: 25828621
Drug: 12 mg/day
Normalized name: EMSAM 12 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/day TT and 103 mg/day PMF
Study: 25828621
Drug: 27 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27 mg/day TT and 32 mg/day PMF
Study: 25828621
Drug: 12 mg/day
Normalized name: EMSAM 12 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/day TT and 103 mg/day PMF, 27 mg/day TT and 32 mg/day PMF, and Placebo
Study: 23950599
Drug: ALAnerv® (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALAnerv® (2 pills/day for two weeks)
Study: 20624784
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus everolimus
Study: 20624784
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus lapatinib
Study: 20624784
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone or plus trastuzumab
Study: 19319017
Drug: Green banana
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green banana (GB) diet (250 g/L) with rice-based diet (54 kcal/dL) for 5 days
Study: 18038549
Drug: Superlymph (immunotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superlymph (immunotropic drug with direct antimicrobial action)
Study: 18038549
Drug: Superlymph (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superlymph (monotherapy for CABP)
Study: 18038549
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (during treatment)
Study: 15507066
Drug: PRP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP vaccine (Group 1, n=39)
Study: 15507066
Drug: PRP-OMP conjugate
Normalized name: Haemophilus influenzae type b vaccine, PRP-OMP conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-OMP conjugate vaccine (Group 2, n=44)
Study: 15507066
Drug: PRP-D conjugate
Normalized name: Haemophilus influenzae type b vaccine, PRP-D conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-D conjugate vaccine (Group 3, n=42)
Study: 7199997
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion at a constant rate of 1 mmol/min
Study: 26851872
Drug: Alteplase (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (1 mg/mL)
Study: 26851872
Drug: Urokinase (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (5000 IU/mL)
Study: 20004617
Drug: Ipilimumab 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab 0.3 mg/kg
Study: 10667641
Drug: Micronized purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized purified flavonoid fraction (MPFF), 1,000 mg/day
Study: 9818634
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 or 30 mg/day
Study: 9818634
Drug: Citalopram 40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 40 or 60 mg/day
Study: 9818634
Drug: Clomipramine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 60 or 90 mg/day
Study: 8418781
Drug: 2 days
Normalized name: Chapstick 12 Days of Christmas KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days of antibiotic therapy for low-risk group (n=144)
Study: 8418781
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of antibiotic therapy for mid to high-risk group
Study: 8418781
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of antibiotic therapy (historic control subjects)
Study: 3091975
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 600 mg per os
Study: 28612911
Drug: Aspirin, clopidogrel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, clopidogrel, and tirofiban (Group B)
Study: 28612911
Drug: Aspirin, ticagrelor,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, ticagrelor, and tirofiban (Group C)
Study: 28612911
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel (Control Group A)
Study: 25411159
Drug: Biolimus‐A9‐eluting biodegradable-polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biolimus‐A9‐eluting biodegradable-polymer drug‐eluting stents (BP‐DES)
Study: 25411159
Drug: Second‐generation everolimus‐eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second‐generation everolimus‐eluting durable‐polymer drug‐eluting stents (DP‐DES)
Study: 15182277
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day theophylline for 4 weeks
Study: 25876611
Drug: Ambrisentan 5
Normalized name: ambrisentan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 5 mg daily for one month and then 10 mg daily for two months
Study: 17299194
Drug: Routine upstream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine upstream Gp IIb/IIIa inhibitor administration (n=4605)
Study: 17299194
Drug: Deferred selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred selective Gp IIb/IIIa inhibitor administration (n=4602)
Study: 11675948
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 2.7 g/day
Study: 7727280
Drug: Cysteine 500
Normalized name: cysteine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine 500 mg twice daily
Study: 31507250
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy with integrated exposure and emotion-focused elements (CBT-EE)
Study: 30266529
Drug: Gelatin sponge
Normalized name: ABSORBABLE GELATIN SPONGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin sponge patches
Study: 28277996
Drug: Electric stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electric stimulation therapy (EST) used 4 times daily for 20 minutes per session.
Study: 28277996
Drug: Sham device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham device (control group) used 4 times daily for 20 minutes per session.
Study: 21804463
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 µg/day for 18 months)
Study: 21804463
Drug: Bisphosphonates (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates (70 mg/week for 18 months)
Study: 15297775
Drug: Isotonic polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic polyethylene glycol solution containing 50 microCi of [51Cr]EDTA administered through a nasoduodenal tube for intestinal lavage
Study: 15297775
Drug: Intestinal permeability
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intestinal permeability assessment by 5-hour urinary excretion of [51Cr]EDTA
Study: 1722511
Drug: Antiformin/citric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiformin/citric acid chemical treatment
Study: 31475794
Drug: Sacubitril-valsartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily)
Study: 31475794
Drug: Valsartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (target dose, 160 mg twice daily)
Study: 27680994
Drug: Counseling plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling plus 1 of 4 complementary food supplements (CFSs) fed as a daily snack
Study: 17096178
Drug: 0.25 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 percent glycerin trinitrate ointment and cryothermal anal dilators
Study: 17096178
Drug: 0.25 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 percent glycerin trinitrate ointment only
Study: 15011418
Drug: Olprinone hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Olprinone (DB16847)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Olprinone hydrochloride (15 micrograms.kg‐1 bolus plus 0.1 microgram.kg‐1.min‐1 continuous administration)
Study: 31871055
Drug: Faecal volatile
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faecal volatile organic compounds (VOCs) associated with NEC
Study: 26140401
Drug: Strong opioids
Normalized name: Strongid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strong opioids (oxycodone/morphine/meperidine)
Study: 24171779
Drug: Chungkookjang (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chungkookjang (35 g daily for 12 weeks)
Study: 20484620
Drug: Oral clonidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clonidine, 1.5 µg/kg every 4 hours starting the second week of life
Study: 18332051
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rifampicin
Study: 14517773
Drug: Synthetic GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic GLP-1 (7-36 amide) at 1.2 pmol/kg/min administered over a period of three hours during glucose injection.
Study: 14517773
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered during the fasting state.
Study: 14517773
Drug: GLP-1 administered
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 administered until 120 or 30 min before the glucose load.
Study: 14517773
Drug: GLP-1 administered
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 administered until -30 min before glucose load.
Study: 14517773
Drug: GLP-1 administration
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 administration during glucose injection.
Study: 10929918
Drug: Metformin 1,700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1,700 mg/d
Study: 9638433
Drug: alpha-interferon treatment
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alpha-interferon treatment
Study: 8421087
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg, twice daily for 7 days)
Study: 3570479
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid 1% eye preparation, given four to six times daily for one week
Study: 3570479
Drug: Chloramphenicol 0.5%
Normalized name: CHLORAMPHENICOL 0.5% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol 0.5% eye drops, given four to six times daily for one week
Study: 28763401
Drug: Laser (L)
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser (L)
Study: 27402466
Drug: Laser with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser with topical antifungal therapy (L + T)
Study: 27402466
Drug: Topical antifungal
Normalized name: Imidazole and triazole derivatives, topical antifungals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antifungal treatment (T)
Study: 17161051
Drug: Granulocyte colony
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor (G-CSF) at 5 to 10 microg/kg per day subcutaneously for 5 days
Study: 17161051
Drug: Granulocyte colony
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor (G-CSF) at 5 microg/kg per day
Study: 17161051
Drug: Granulocyte colony
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor (G-CSF) at 10 microg/kg per day
Study: 8718436
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg/day p.o.)
Study: 20512042
Drug: Silexan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silexan (80 mg/day)
Study: 29189308
Drug: Lactotripeptides (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactotripeptides (4.5 mg/d, thrice on exercise day and day after)
Study: 29189308
Drug: Placebo (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4.5 mg/d, thrice on exercise day and day after)
Study: 27648290
Drug: Diabetes-specific oral
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes-specific oral nutritional supplement (ONS)
Study: 20795384
Drug: Pneumo 23
DrugBank: Streptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB16711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumo 23 and Act-HIB vaccines
Study: 18463424
Drug: Topical Visthesia
Normalized name: Isothesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Visthesia drops
Study: 15962453
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) daily
Study: 15962453
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) alternate days
Study: 8622103
Drug: isepamicin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: isepamicin (15 mg/kg once daily)
Study: 8622103
Drug: amikacin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amikacin (7.5 mg/kg twice daily)
Study: 728895
Drug: Levamisole (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (doses ranged from 65 to 410 mg/m2, maximum tolerated dose 358 mg/m2)
Study: 23895296
Drug: Reduced toxicant
Normalized name: Antiaris toxicara resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced toxicant prototype (RTP) cigarette (7 mg ISO tar yield)
Study: 9066740
Drug: Peri-operative adjuvant
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peri-operative adjuvant chemotherapy (PAC) with CEF (cyclophosphamide 600 mg/sqm, epidoxorubicin 60 mg/sqm, 5-fluorouracil 600 mg/sqm)
Study: 8394470
Drug: Priming with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priming with 10% of total dose (T) of pipecuronium
Study: 8394470
Drug: Priming with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priming with 5%, 15%, or 20% of total dose (T) of pipecuronium
Study: 3523393
Drug: Transdermal iontophoresis
Normalized name: Sumatriptan Iontophoretic Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal iontophoresis of vincristine
Study: 22129564
Drug: Passive scattering
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive scattering proton therapy (PSPT)
Study: 15549326
Drug: Budesonide (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (9 mg/day for 6 weeks)
Study: 10333947
Drug: Troglitazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (600 mg)
Study: 1832287
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg slow i.v.)
Study: 6187064
Drug: Isoprinosine administered
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprinosine administered for 60 days
Study: 6187064
Drug: Prednisone administered
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone administered for 60 days (Control)
Study: 29069046
Drug: Burr hole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burr hole, urokinase infusion and catheter drainage (Group B, n=22)
Study: 21727100
Drug: Standardization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardization of medication-ordering, reliable medication-dispensing processes, reliable medication-administration processes, improvement of patient safety culture, clinical decision support.
Study: 11313161
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg clonazepam
Study: 14601351
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy self-help facilitated by practice nurses
Study: 10387403
Drug: Treatment trials
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment trials
Study: 10387403
Drug: Selective participation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective participation in treatment RCTs
Study: 2025847
Drug: Definitive radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Definitive radiation therapy
Study: 2025847
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated irradiation with less intense chemotherapy
Study: 2025847
Drug: Hyperfractionated irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated irradiation with simultaneous chemotherapy
Study: 6625781
Drug: Continuous oxygen
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oxygen treatment (COT)
Study: 6625781
Drug: Nocturnal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal oxygen treatment (NOT)
Study: 29975462
Drug: Ranirestat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranirestat (40 mg/day)
Study: 9523307
Drug: Oral bidisomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bidisomide co-administration with breakfast
Study: 9523307
Drug: Intravenous bidisomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bidisomide infusion with high fat breakfast
Study: 9523307
Drug: Oral bidisomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bidisomide co-administration with viscous homogenized solid meals
Study: 9523307
Drug: Oral non-caloric
Normalized name: Tavist Non-Sedating Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral non-caloric hydroxypropyl methylcellulose meals
Study: 9523307
Drug: Oral, duodenal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, duodenal, and mid-jejunal administration of disopyramide in dogs
Study: 9523307
Drug: Oral bidisomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bidisomide administration in dogs with solid meal co-administration
Study: 2678210
Drug: Nadolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (beta blocker)
Study: 2678210
Drug: Combined beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined beta blocker and relaxation therapy
Study: 3698521
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg daily
Study: 29171487
Drug: neuromultivit and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: neuromultivit and basic therapy
Study: 29171487
Drug: basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: basic therapy
Study: 22139799
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia with lidocaine spray (10gr/100ml) in Group A (≤65 years)
Study: 22139799
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia with lidocaine spray (10gr/100ml) in Group B (>65 years)
Study: 19695646
Drug: Full spectrum
Normalized name: Full Spectrum B with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full spectrum therapy with pelvic floor muscle training
Study: 19695646
Drug: Full spectrum
Normalized name: Full Spectrum B with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full spectrum therapy without pelvic floor muscle training (Control)
Study: 16645428
Drug: Reliéva (Mahonia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reliéva (Mahonia aquifolium extract) topical cream, applied twice a day for 12 weeks
Study: 16645428
Drug: Placebo topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical cream, applied twice a day for 12 weeks
Study: 11895160
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) supplemented with soybean oil (SO, Lipovenoess 10% PLR; 1.0 g/kgBW per day; n = 20)
Study: 11895160
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) supplemented with a combination of fish oil (FO, Omegaven; 0.2 g/kgBW per day) and soybean oil (SO, Lipovenoes 10% PLR; 0.8 g/kgBW per day; n = 24)
Study: 9495408
Drug: no droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: no droperidol injection
Study: 300048
Drug: Sulindac (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (twice daily dosage for 5 days)
Study: 300048
Drug: Sulindac (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (twice daily dosage)
Study: 23973636
Drug: American ginseng
Normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: American ginseng (AG) 3g daily for 12 weeks
Study: 20713813
Drug: Narrowband UV-B
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband UV-B treatment 3 times per week
Study: 12093831
Drug: OC +
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC + metformin
Study: 9560053
Drug: Full-dose anthracycline-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose anthracycline-containing regimens similar to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
Study: 9560053
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of CHOP chemotherapy followed by involved field irradiation
Study: 9560053
Drug: Hematopoietic growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematopoietic growth factors and/or cardioprotective drugs